ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$64.90 USD
+1.44 (2.27%)
Updated May 31, 2024 04:00 PM ET
After-Market: $64.95 +0.05 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth D Momentum A VGM
Brokerage Reports
ANI Pharmaceuticals, Inc. [ANIP]
Reports for Purchase
Showing records 41 - 60 ( 88 total )
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Recap - Messy Quarter, but Progress Underway
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Updated Model - Adjusting PT to Reflect More Conservative Environment
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Flecainide Could Add ~$0.20 to EPS Line in 2016+
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q14 Quick Take - Great Quarter, Guidance Looks Conservative
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Upping PT to $65; Upside from Methazolamide and Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q14 Recap - Higher Revenue and EPS Trajectory; PT to $55
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: ANI Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.